Silence Therapeutics Announces Board Change

Silence Therapeutics Announces Board Change

April 16, 2019

LONDON, Silence Therapeutics, PLC (LON: SLN) ("Silence" or "the Company") a leader in the discovery, development and delivery of novel RNA therapeutics for the treatment of serious diseases, announces today that Dr. Andy Richards, CBE, is leaving his role as interim non-executive Chair and a Director of the Company with immediate effect. The Company's previously announced process to appoint a new Chair is ongoing.

Dr. David Horn Solomon, Chief Executive Officer, commented: "Andy Richards has served on the Board of Silence since 2016, first as a non-executive director and more recently as interim Chairman. During this time, Andy has been instrumental in a implementing a bold turnaround of Company strategy which has re-energised our drug-development programmes and led us to a point where we are now preparing to commence in-human trials with our lead RNAi candidate SLN124. I would like to thank Andy for his invaluable contribution to the Company and wish him well in his future endeavours."

Enquiries:

About Silence Therapeutics plc

Silence Therapeutics is developing a new generation of medicines by harnessing the body's natural

mechanism of RNA interference, or RNAi, within its cells. Its proprietary technology can selectively

inhibit any gene in the genome, specifically silencing the production of disease-causing proteins. Using

its enabling delivery systems, it has achieved an additional level of specificity by delivering its

therapeutic RNA molecules exclusively to target cells. Silence's proprietary RNA chemistries and

delivery systems are designed to improve the stability of our molecules and enhance effective delivery

to target cells, providing a powerful modular technology well suited to tackle life-threatening diseases.

For more information, please visit: https://www.silence-therapeutics.com/